Financings in Brief: Lifecell:
This article was originally published in The Gray Sheet
Lifecell: Completes private offering of convertible preferred stock and common stock warrants, expected to generate $12.4 mil. for The Woodlands, Texas-based developer of the AlloDerm tissue graft. Lifecell sold series B preferred stock convertible to common stock at a price of $3.10 per share and warrants for common stock exercisable at $4.13 per share. The offering was made to institutional and other investors...
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.
Our updated graphic tracker of key developments from the leading vaccine candidates.